Preprints.org

Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms

By Karthik Murugadoss, A J Venkatakrishnan, Venky Soundararajan

Preprint: cohort study in peopleInterventions

The paper

Karthik Murugadoss, A J Venkatakrishnan, Venky Soundararajan

Preprints.org, 18 Aug 2026, Preprint, not peer-reviewed

doi.org/10.20944/preprints202608.1193.v1

Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk